Liu , Z , Wang , S , Tapeinos , C , Torrieri , G , Känkänen , V , Ibrahim , N E A A , Python , A , Hirvonen , J & Santos , H A 2021 , ' Non-viral nanoparticles for RNA interference : Principles of design and practical guidelines ' , Advanced Drug Delivery Reviews , vol. 174 , pp. 576-612 . https://doi.org/10.1016/j.addr.2021.05.018
Title: | Non-viral nanoparticles for RNA interference : Principles of design and practical guidelines |
Author: | Liu, Zehua; Wang, Shiqi; Tapeinos, Christos; Torrieri, Giulia; Känkänen, Voitto; Ibrahim, Nesma Elsayed Ahmed Ahmed; Python, Andre; Hirvonen, Jouni; Santos, Hélder A. |
Contributor organization: | Nanomedicines and Biomedical Engineering Division of Pharmaceutical Chemistry and Technology Drug Research Program Faculty of Pharmacy Jouni Hirvonen / Principal Investigator Divisions of Faculty of Pharmacy Helsinki One Health (HOH) |
Date: | 2021-07 |
Language: | eng |
Number of pages: | 37 |
Belongs to series: | Advanced Drug Delivery Reviews |
ISSN: | 0169-409X |
DOI: | https://doi.org/10.1016/j.addr.2021.05.018 |
URI: | http://hdl.handle.net/10138/332667 |
Abstract: | Ribonucleic acid interference (RNAi) is an innovative treatment strategy for a myriad of indications. Non-viral synthetic nanoparticles (NPs) have drawn extensive attention as vectors for RNAi due to their potential advantages, including improved safety, high delivery efficiency and economic feasibility. However, the complex natural process of RNAi and the susceptible nature of oligonucleotides render the NPs subject to particular design principles and requirements for practical fabrication. Here, we summarize the requirements and obstacles for fabricating non-viral nano-vectors for efficient RNAi. To address the delivery challenges, we discuss practical guidelines for materials selection and NP synthesis in order to maximize RNA encapsulation efficiency and protection against degradation, and to facilitate the cytosolic release of oligonucleotides. The current status of clinical translation of RNAi-based therapies and further perspectives for reducing the potential side effects are also reviewed. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
Subject: |
BUBBLE LIPOSOMES
CELL-PENETRATING PEPTIDE Clinical translation ENDOSOMAL ESCAPE Endosome escape GENE DELIVERY IN-VIVO LIPID NANOPARTICLES Leukocytes targeting MEDIATED TARGETED DELIVERY Non-viral nanoparticles POLYMER BRUSHES RNA encapsulation RNA interference SIRNA DELIVERY TUMOR-ASSOCIATED MACROPHAGES 318 Medical biotechnology 221 Nano-technology 317 Pharmacy |
Peer reviewed: | Yes |
Rights: | cc_by |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
1_s2.0_S0169409X21001824_main.pdf | 10.20Mb |
View/ |
|
Non_viral_nanop ... d_practical_guidelines.pdf | 7.991Mb |
View/ |